21.07.2013 Views

tax notes international - Tuck School of Business - Dartmouth College

tax notes international - Tuck School of Business - Dartmouth College

tax notes international - Tuck School of Business - Dartmouth College

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

SPECIAL REPORTS<br />

The second exception is that the differential is due<br />

to extraordinary events beyond the control <strong>of</strong> the controlled<br />

participants that could not reasonably have been<br />

anticipated as <strong>of</strong> the date <strong>of</strong> the trigger PCT.<br />

The third exception is that the periodic trigger<br />

would not have occurred had the PCT payer’s divisional<br />

pr<strong>of</strong>its or losses used to calculate its present<br />

value <strong>of</strong> total pr<strong>of</strong>its (PVTP) excluded those pr<strong>of</strong>its or<br />

losses attributable to the PCT payer’s routine contributions<br />

to its exploitation <strong>of</strong> the cost-shared intangibles,<br />

attributable to its operating cost contributions, and attributable<br />

to its nonroutine contributions to the CSA<br />

activity.<br />

In an important narrowing,<br />

the temporary regulations<br />

provide that a periodic<br />

trigger occurs if the AERR<br />

falls outside the PRRR <strong>of</strong><br />

between 0.667 and 1.5.<br />

The fourth exception is that the periodic trigger<br />

would not have occurred had the divisional pr<strong>of</strong>its or<br />

losses <strong>of</strong> the PCT payer used to calculate its PVTP<br />

included its reasonably anticipated divisional pr<strong>of</strong>its or<br />

losses after the adjustment year from the CSA activity,<br />

including its routine contributions, its operating cost<br />

contributions, and its nonroutine contributions to that<br />

activity, and had the cost contributions and PCT payments<br />

<strong>of</strong> the PCT payer used to calculate its PVI<br />

(present value <strong>of</strong> the PCT payer’s investment at the<br />

start date) included its reasonably anticipated cost contributions<br />

and PCT payments after the adjustment year.<br />

Also, a periodic trigger will not be deemed to have<br />

occurred in any year subsequent to the 10-year period<br />

beginning with the first <strong>tax</strong> year in which there is substantial<br />

exploitation <strong>of</strong> the cost-shared intangibles resulting<br />

from the CSA, if the AERR is within the<br />

PRRR for each year <strong>of</strong> the 10-year period. It also will<br />

not be deemed to have occurred in any year <strong>of</strong> the<br />

five-year period beginning with the first <strong>tax</strong> year in<br />

which there is exploitation <strong>of</strong> the cost-shared intangibles<br />

resulting from the CSA if the AERR falls below<br />

the lower bound <strong>of</strong> the PRRR.<br />

The IRS and Treasury intend to issue by revenue<br />

procedure separate published guidance that provides an<br />

exception to periodic adjustments in the context <strong>of</strong> an<br />

advance pricing agreement. The guidance would provide<br />

that no periodic adjustments will be made in any<br />

year based on a trigger PCT that is a covered transaction<br />

under the APA. An APA process generally is contemporaneous<br />

with the <strong>tax</strong>payer’s original transactions<br />

and involves transparency concerning a <strong>tax</strong>payer’s upfront<br />

efforts to conform to the arm’s-length standard.<br />

Treatment <strong>of</strong> Payments<br />

CST payments generally will be considered the<br />

payer’s cost <strong>of</strong> developing intangibles at the location<br />

where the development is conducted. For these purposes,<br />

IDCs borne directly by a controlled participant<br />

that are deductible are deemed to be reduced to the<br />

extent <strong>of</strong> any CST payments owed to it by other controlled<br />

participants under the CSA.<br />

The PCT payer’s payment is deemed to be reduced<br />

to the extent <strong>of</strong> any payments owed to it from other<br />

controlled participants. PCT payments will be characterized<br />

consistently with the <strong>tax</strong>payer’s designation <strong>of</strong><br />

the type <strong>of</strong> transaction. Depending on the designation,<br />

the payments will be treated as either consideration for<br />

a transfer <strong>of</strong> an interest in intangible property or for<br />

services.<br />

Administrative Requirements<br />

Temp. Treas. reg. section 1.482-7T(k) contains the<br />

CSA administrative requirements. There are four main<br />

sections: contractual; documentation; accounting; and<br />

reporting requirements. This section <strong>of</strong> the temporary<br />

regulations is lengthy.<br />

The contractual rules are important. CSA agreements<br />

already in effect will need to be modified by<br />

July 6, 2009, by integrating those rules with the transition<br />

rules in temp. Treas. reg. section 1.482-7T(m). A<br />

CSA statement also will need to be filed by September<br />

2, 2009.<br />

Documentation is especially important under the<br />

temporary regulations. For example, careful analysis<br />

and documentation <strong>of</strong> discount rate choices could be<br />

very important. Also, the periodic adjustment trigger<br />

range is narrower for <strong>tax</strong>payers that fail to maintain<br />

adequate documentation.<br />

New Best Method Examples<br />

Example 13. USP and FS enter into a CSA to develop<br />

a new drug. Immediately before entering into the<br />

CSA, USP acquires Company X. X is engaged in research<br />

relevant to the product area, and its only significant<br />

resources and capabilities are its workforce and<br />

sole patent. The patent is associated with a compound<br />

that USP reasonably anticipates will contribute to developing<br />

the CSA product. The acquisition price<br />

method, based on the lump sum price paid by USP for<br />

Company X, is likely to provide a more reliable measure<br />

<strong>of</strong> an arm’s-length result than any other method.<br />

Example 14. Company X is a publicly traded U.S.<br />

company engaged in pharmaceutical research. Its only<br />

significant resources and capabilities are workforce and<br />

its sole patent. Company X has no marketable products.<br />

Company X enters into a CSA with FS, its newly<br />

formed foreign subsidiary, to develop a new drug. The<br />

new drug will be derived from the compound covered<br />

468 • FEBRUARY 2, 2009 TAX NOTES INTERNATIONAL<br />

(C) Tax Analysts 2009. All rights reserved. Tax Analysts does not claim copyright in any public domain or third party content.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!